Limits...
Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis.

Kutsukake M, Ishihara R, Momose K, Isaka K, Itokazu O, Higuma C, Matsutani T, Matsuda A, Sasajima K, Hara T, Tamura K - Reprod. Biol. Endocrinol. (2008)

Bottom Line: Decreased IGFBP7 expression has been observed in some cancers and leiomyomata.Using this new ELISA, we demonstrated that cultured uterine cells secrete IGFBP7 into the medium.There were no differences in serum IGFBP7 levels in women at different stages of the menstrual cycle.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 193-0392, Japan. kutsu@ps.toyaku.ac.jp

ABSTRACT

Background: Insulin-like growth factor-binding protein-7 (IGFBP7) is a secretory protein with a molecular mass of approximately 30 kDa. It is abundantly expressed in the uterine endometrium during the secretory phase of the menstrual cycle. Decreased IGFBP7 expression has been observed in some cancers and leiomyomata.

Methods: To determine whether serum IGFBP7 levels reflect changes in uterine IGFBP7 expression in humans during the menstrual cycle, and to examine whether serum IGFBP7 levels are altered in patients with various disorders, we developed a novel, dual-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Firstly, concentrations of IGFBP7 released into the medium were determined in cultured endometrial stromal and glandular cells. Blood samples were collected from women who had normal menstrual cycles and who had been diagnosed with endometriosis. Serum from hemodialysis patients and gastrointestinal cancers was also used to determine the IGFBP7 levels.

Results: Using this new ELISA, we demonstrated that cultured uterine cells secrete IGFBP7 into the medium. Patients with endometriosis and those with type II diabetes mellitus undergoing hemodialysis had significantly higher serum concentrations of IGFBP7 than the relevant control subjects. There were no differences in serum IGFBP7 levels in women at different stages of the menstrual cycle. Furthermore, serum IGFBP7 levels in patients with colorectal, esophageal, or endometrial cancer were not different than normal healthy subjects.

Conclusion: Our observations suggest that IGFBP7 is associated with the pathophysiology of endometriosis and diabetes mellitus, and that serum IGFBP7 levels do not reflect enhanced uterine expression of IGFBP7 mRNA during the menstrual cycle.

Show MeSH

Related in: MedlinePlus

Serum IGFBP7 levels in patients at different phases of the menstrual cycle (A) and with endometriosis (B). (A) The sera from 62 women with regular menstrual cycles were tested. The numbers in parentheses indicate the number of subjects at each stage. (B) The sera from 11 patients with endometriosis were tested along with those of the 62 women with regular menstrual cycles, described for A, who served as controls for this study (Control). Data represents the means ± SE. *P < 0.05 as compared to Control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2600820&req=5

Figure 2: Serum IGFBP7 levels in patients at different phases of the menstrual cycle (A) and with endometriosis (B). (A) The sera from 62 women with regular menstrual cycles were tested. The numbers in parentheses indicate the number of subjects at each stage. (B) The sera from 11 patients with endometriosis were tested along with those of the 62 women with regular menstrual cycles, described for A, who served as controls for this study (Control). Data represents the means ± SE. *P < 0.05 as compared to Control.

Mentions: There are marked changes in uterine IGFBP7 mRNA levels during the menstrual cycle. To determine if these changes are reflected in serum IGFBP7 levels, we measured IGFBP7 concentrations in sera from 62 women at different phases of the menstrual cycle (Fig. 2A). Serum IGFBP7 levels did not change significantly throughout the menstrual cycle. The average IGFBP7 level in serum was 33 ± 13.1 ng/ml (median of 35 ng/ml). We also observed that mean serum IGFBP7 levels do not differ between males and females (data not shown).


Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis.

Kutsukake M, Ishihara R, Momose K, Isaka K, Itokazu O, Higuma C, Matsutani T, Matsuda A, Sasajima K, Hara T, Tamura K - Reprod. Biol. Endocrinol. (2008)

Serum IGFBP7 levels in patients at different phases of the menstrual cycle (A) and with endometriosis (B). (A) The sera from 62 women with regular menstrual cycles were tested. The numbers in parentheses indicate the number of subjects at each stage. (B) The sera from 11 patients with endometriosis were tested along with those of the 62 women with regular menstrual cycles, described for A, who served as controls for this study (Control). Data represents the means ± SE. *P < 0.05 as compared to Control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2600820&req=5

Figure 2: Serum IGFBP7 levels in patients at different phases of the menstrual cycle (A) and with endometriosis (B). (A) The sera from 62 women with regular menstrual cycles were tested. The numbers in parentheses indicate the number of subjects at each stage. (B) The sera from 11 patients with endometriosis were tested along with those of the 62 women with regular menstrual cycles, described for A, who served as controls for this study (Control). Data represents the means ± SE. *P < 0.05 as compared to Control.
Mentions: There are marked changes in uterine IGFBP7 mRNA levels during the menstrual cycle. To determine if these changes are reflected in serum IGFBP7 levels, we measured IGFBP7 concentrations in sera from 62 women at different phases of the menstrual cycle (Fig. 2A). Serum IGFBP7 levels did not change significantly throughout the menstrual cycle. The average IGFBP7 level in serum was 33 ± 13.1 ng/ml (median of 35 ng/ml). We also observed that mean serum IGFBP7 levels do not differ between males and females (data not shown).

Bottom Line: Decreased IGFBP7 expression has been observed in some cancers and leiomyomata.Using this new ELISA, we demonstrated that cultured uterine cells secrete IGFBP7 into the medium.There were no differences in serum IGFBP7 levels in women at different stages of the menstrual cycle.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 193-0392, Japan. kutsu@ps.toyaku.ac.jp

ABSTRACT

Background: Insulin-like growth factor-binding protein-7 (IGFBP7) is a secretory protein with a molecular mass of approximately 30 kDa. It is abundantly expressed in the uterine endometrium during the secretory phase of the menstrual cycle. Decreased IGFBP7 expression has been observed in some cancers and leiomyomata.

Methods: To determine whether serum IGFBP7 levels reflect changes in uterine IGFBP7 expression in humans during the menstrual cycle, and to examine whether serum IGFBP7 levels are altered in patients with various disorders, we developed a novel, dual-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Firstly, concentrations of IGFBP7 released into the medium were determined in cultured endometrial stromal and glandular cells. Blood samples were collected from women who had normal menstrual cycles and who had been diagnosed with endometriosis. Serum from hemodialysis patients and gastrointestinal cancers was also used to determine the IGFBP7 levels.

Results: Using this new ELISA, we demonstrated that cultured uterine cells secrete IGFBP7 into the medium. Patients with endometriosis and those with type II diabetes mellitus undergoing hemodialysis had significantly higher serum concentrations of IGFBP7 than the relevant control subjects. There were no differences in serum IGFBP7 levels in women at different stages of the menstrual cycle. Furthermore, serum IGFBP7 levels in patients with colorectal, esophageal, or endometrial cancer were not different than normal healthy subjects.

Conclusion: Our observations suggest that IGFBP7 is associated with the pathophysiology of endometriosis and diabetes mellitus, and that serum IGFBP7 levels do not reflect enhanced uterine expression of IGFBP7 mRNA during the menstrual cycle.

Show MeSH
Related in: MedlinePlus